** Shares of gene therapy maker bluebird bio rise as much as 2.3% to 49 cents premarket; last up 1%
** Co says it will cut approximately 25% of its workforce as part of its restructuring to optimize cash flow break-even in H2 2025
** Restructuring also to reduce operating cash expenses by 20% - co
** BLUE says it will incur aggregate charged worth $3.7 mln as a result of restructuring, to be paid out through fiscal year ending Dec. 31
** As of June 30, 2024, co had 375 full-time employees
** As of last close, stock down 64.6% YTD
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。